What Is the COVID Pill and How Does It Work?

The “COVID pill” usually refers to Paxlovid (nirmatrelvir/ritonavir), an oral antiviral that blocks a key enzyme the SARS-CoV-2 virus needs to reproduce inside your cells. A second oral antiviral, molnupiravir (sold as Lagevrio), works by a completely different mechanism, sabotaging the virus’s genetic code during replication. Both were developed to be taken at home during the first few days of a COVID-19 infection, making them a practical alternative to treatments that require an IV line or a hospital visit.¹ Paxlovid has become the dominant treatment of the two, and most of what follows focuses on it, though molnupiravir has its own story worth understanding.

How Paxlovid Stops the Virus

Paxlovid is actually two drugs packaged together. The one doing the antiviral work is nirmatrelvir. It targets a viral enzyme called the main protease (often abbreviated Mpro), which the virus relies on to chop up a long chain of proteins into the individual pieces it needs to assemble new copies of itself. Nirmatrelvir latches onto the active site of this enzyme and forms a tight chemical bond with a critical residue there, effectively jamming the enzyme shut.² Without a working protease, the virus cannot produce the functional proteins it needs, and replication grinds to a halt.

The second drug in the package, ritonavir, does not fight the virus at all. Its job is to keep nirmatrelvir in your bloodstream long enough to work. Your liver would normally break nirmatrelvir down quickly through a specific metabolic pathway. Ritonavir blocks that pathway, slowing nirmatrelvir’s breakdown so that concentrations stay above the level needed to suppress viral replication.³ Ritonavir has been used this way for decades in HIV medicine; it is not new, and its pharmacology is well characterized. The standard course is five days of both pills taken together twice daily.

How Molnupiravir Works Differently

Molnupiravir takes a fundamentally different approach. Rather than blocking a viral enzyme, it disguises itself as one of the building blocks the virus uses to copy its genetic material. Once inside your cells, molnupiravir is converted into an active form that gets mistakenly incorporated into new strands of viral RNA by the virus’s own copying machinery. The trick is that this fake building block pairs unpredictably during subsequent rounds of copying, introducing a flood of random errors into the viral genome. When enough of these mutations pile up, the resulting viral copies are so riddled with mistakes that they can no longer function.⁴ Researchers call this process lethal mutagenesis or “error catastrophe.” It is an elegant concept: rather than directly shutting off the virus’s factory, you wreck its blueprints so badly the factory produces nothing usable.

How Well Does Paxlovid Actually Work?

The pivotal clinical trial for Paxlovid, published in the New England Journal of Medicine, enrolled unvaccinated adults at high risk of severe COVID-19. Among those who started treatment within three days of symptoms, roughly 89% fewer patients ended up hospitalized or dead compared with the placebo group. In raw numbers, about 0.8% of the Paxlovid group was hospitalized versus 7% in the placebo group. All thirteen deaths during the study occurred among people who received the placebo.⁵

Those numbers were dramatic, but they came from a specific time and population: unvaccinated people during earlier waves of the pandemic. The question of how well Paxlovid performs in the Omicron era, when most people have some immunity from vaccines or prior infection, has been harder to pin down. A large observational study using electronic health records from the U.S. National COVID Cohort Collaborative found that treated patients still had roughly a third the odds of hospitalization compared with matched untreated patients.⁶ The absolute benefit is smaller than in the original trial, since baseline hospitalization rates have dropped, but the drug still meaningfully reduces the chance of winding up in the hospital for people at elevated risk.

Why Timing Is So Important

Paxlovid needs to be started early. The standard guidance is within five days of symptom onset, but the evidence suggests that even within that window, earlier is better. A modeling study fitting viral dynamics to patient records estimated that starting Paxlovid around three days after symptoms appear gives a reasonable balance between suppressing the virus and allowing the immune system to develop its response. Starting beyond five days does little to curb peak viral shedding.⁷ This creates a practical bottleneck: you need to test positive, get a prescription, and fill it all within a few days. In places with limited testing, that timeline can be hard to meet.⁸

The Rebound Problem

One of the most discussed quirks of Paxlovid treatment is “rebound,” where someone finishes the five-day course, feels better, and then has symptoms or a positive test return a few days later. This happens in a meaningful fraction of patients. In a randomized trial comparing nirmatrelvir-ritonavir with another antiviral, about 22% of people in the Paxlovid arm experienced a viral load rebound, and roughly a quarter had some return of symptoms.⁹

The leading explanation is straightforward. Paxlovid is so effective at blocking viral replication that it also preserves the cells the virus was in the process of infecting. At the same time, it may delay the adaptive immune response from fully kicking in. When you stop the drug after five days, if the virus has not been completely cleared and your immune system has not yet mounted a strong enough defense, the remaining virus can resume replicating using those preserved cells.¹⁰ The same modeling work suggests that earlier treatment initiation may actually increase the probability of rebound, because it intervenes before the immune system has begun building a response. Paradoxically, starting treatment a bit later, around three days after symptom onset, may thread the needle better.

Extending the treatment course to ten days has been proposed as a way to reduce rebound, and modeling studies indicate it could substantially decrease the odds.¹⁰ However, this is not yet standard clinical practice, and most prescriptions still follow the five-day regimen. The rebounds are generally mild and self-limiting, but they are confusing for patients and can extend the period during which someone is contagious.

Drug Interactions and Who Cannot Take Paxlovid

The ritonavir component that keeps nirmatrelvir active in the body creates a significant practical problem: it interferes with the same liver enzyme pathway used to metabolize a long list of other drugs. If you take a medication that depends on that pathway, adding ritonavir can cause levels of the other drug to spike dangerously. This is particularly concerning for organ transplant recipients who take tacrolimus, an immunosuppressant. When Paxlovid blocks tacrolimus metabolism, blood levels of tacrolimus can rise to toxic concentrations.¹¹ The same risk applies to certain heart rhythm medications, some cholesterol drugs, and several other common prescriptions. This means that before prescribing Paxlovid, clinicians need to carefully review the patient’s full medication list, and sometimes a temporarily adjusted dosing plan or a switch to a different COVID treatment is necessary.

Pregnant people represent another gap in the evidence. They were excluded from the major clinical trials, so knowledge about safety in pregnancy comes from theoretical risk assessments and observational data rather than controlled studies.¹² Similarly, data on children is limited, as the original trials enrolled adults.

Safety Questions Around Molnupiravir

Because molnupiravir works by introducing mutations into viral RNA, researchers have understandably asked whether it could also damage human DNA. The concern is logical: a drug designed to cause genetic errors in one organism might not be perfectly selective. Early safety questions led to focused investigation.¹³

The evidence so far is reassuring. A comprehensive genotoxicity and carcinogenicity study in rats found that molnupiravir did not cause a statistically significant increase in mutation frequency in the liver or bone marrow at any tested dose.¹⁴ A separate study using whole-genome sequencing of offspring from treated organisms found no increase in germline mutation frequency from either molnupiravir or its active metabolite.¹⁵ These results align with what has been seen clinically: short courses of molnupiravir do not appear to carry a measurable mutagenic risk. That said, the drug is not recommended during pregnancy as a precaution, and it remains less widely prescribed than Paxlovid in most high-income countries.

Does Paxlovid Prevent Long COVID?

This was one of the biggest hopes for Paxlovid: that by squashing the virus early, you might prevent the lingering symptoms collectively known as long COVID (or PASC). The data so far is disappointing on that front. A large target trial emulation using data from the N3C and RECOVER consortia found that Paxlovid treatment during acute COVID-19 had no meaningful effect on overall long COVID incidence. The rate was about 4.5% in both treated and untreated groups. There were small reductions in cognitive symptoms and fatigue specifically, but the effects were modest, requiring you to treat roughly 500 to 1,000 people to prevent one additional case of those particular symptom clusters.¹⁶

Another study found mixed organ-specific effects: Paxlovid was associated with a reduction in gastrointestinal long COVID symptoms but an increase in eye and ear symptoms like tinnitus or blurred vision.¹⁷ These are observational findings and need to be interpreted carefully, but the headline takeaway is that Paxlovid should be thought of as a treatment for acute illness rather than a reliable shield against long COVID.

Will Resistance Become a Problem?

For now, the antivirals work well against circulating variants. Lab studies have shown that nirmatrelvir retains its effectiveness against a wide range of Omicron sublineages, including BA.1, BA.2, BA.5, BQ.1.1, and XBB.¹⁸ Similarly, testing across newer Omicron subvariants has found that nirmatrelvir, molnupiravir, and remdesivir all maintain their antiviral activity, with only minor changes in potency that do not appear clinically relevant.¹⁹

The longer-term picture is less comfortable. Researchers have identified specific mutations in the main protease that can reduce nirmatrelvir’s effectiveness substantially. One mutation at a position called E166 can slash the drug’s potency by up to 3,000-fold while barely affecting the enzyme’s normal function, and a secondary mutation can compensate for the small fitness cost.²⁰ Several other mutations have been shown to reduce nirmatrelvir’s potency in lab experiments as well.²¹ Phylogenetic analysis has found that some of these resistant variants already exist in the human population, predating the widespread use of the drugs.¹⁹ None have become dominant yet, but this is the same evolutionary pressure that shaped resistance to antibiotics and HIV drugs. Surveillance will need to be ongoing.

Some newer protease inhibitors, like ensitrelvir (approved in Japan as Xocova), have different resistance profiles, meaning a mutation that defeats nirmatrelvir does not necessarily defeat the next drug in line.² Having multiple drugs that target the same enzyme in different ways gives public health a deeper bench to work with if resistance does emerge.

Cost, Access, and the Real-World Bottleneck

Paxlovid’s development was remarkably fast. The active ingredient, nirmatrelvir, went from discovery to emergency use authorization in about seventeen months, requiring an unprecedented pace of chemical process development.²² That speed was a scientific achievement, but it did not automatically translate into broad global access.

The drug needs to be taken within five days of symptoms, and that creates a testing bottleneck. In countries with limited diagnostic infrastructure, identifying and treating eligible patients fast enough is a genuine challenge.⁸ Even in high-income countries, cost has become a growing concern. When the U.S. government was purchasing and distributing Paxlovid at no cost to patients, uptake was higher. As the drug transitioned to commercial pricing, economic modeling suggests it remains cost-effective for high-risk individuals, but with a caveat: at current prices and the lower baseline hospitalization rates of the Omicron era, cost-effectiveness improves substantially with a drug price reduction of roughly a quarter to two-thirds.²³

A German economic evaluation found that for adults aged 60 and older, Paxlovid was actually the dominant strategy, meaning it both improved health outcomes and reduced overall healthcare costs compared to supportive care alone.²⁴ On a population level, modeling of the U.S. pandemic response estimated that treating even 20% of symptomatic patients with Paxlovid over about ten months could have averted hundreds of thousands of hospitalizations and saved tens of billions of dollars in healthcare costs.²⁵ The economics strongly favor treatment in high-risk groups; the debate is over the drug’s value in younger, healthier, vaccinated populations where the baseline risk of severe illness is already low.

How Emergency Authorization Shaped Availability

Both Paxlovid and molnupiravir initially reached patients through emergency use authorizations (EUAs) rather than the standard FDA approval process. The distinction matters. Standard drug approval typically requires randomized clinical trials proving both safety and efficacy to a high bar. EUA policies require data that supports, but does not necessarily prove, safety and effectiveness, with faster reviews and lower evidence thresholds.²⁶ Paxlovid subsequently received full FDA approval in May 2023, which broadened insurance coverage and solidified its place in treatment guidelines. Molnupiravir, which showed weaker efficacy in its trials, never received full FDA approval and its EUA was eventually revoked in the United States, though it remains available in some other countries.

The practical upshot for you: if your doctor prescribes Paxlovid today, it carries full FDA approval backed by both the original trial data and substantial real-world evidence. The drug has a strong track record for reducing hospitalization in people at higher risk, though it is not a cure-all, and its limitations, from drug interactions to rebound to uncertain long COVID benefits, are worth understanding before you pick up the prescription.

1
PubMed Central. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection
2
Communications Biology. Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
3
PubMed Central. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir
4
PubMed Central. Molnupiravir’s mechanism of action drives “error catastrophe” in SARS-CoV-2
5
PubMed Central. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
6
PubMed Central. Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C
7
eLife. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
8
PubMed Central. Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
9
JAMA Network Open. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment
10
PubMed Central. Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
11
PubMed. Paxlovid (Nirmatrelvir/Ritonavir)-Induced Tacrolimus Toxicity in Organ Transplant Recipients – A Review on Drug Interactions Involving CYP3A Enzymes
12
PubMed Central. COVID-19 Therapeutics and Considerations for Pregnancy
13
PubMed Central. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review
14
Toxicological Sciences. Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir
15
PubMed. Germline mutagenicity of molnupiravir and its active form, β-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencing
16
PubMed Central. Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia
17
Communications Medicine. Paxlovid shows organ-specific and age-specific impacts on risk of developing post-acute sequelae of COVID-19
18
Molecular Therapy Nucleic Acids. Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
19
PubMed Central. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
20
PubMed Central. Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50
21
PubMed. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening
22
PubMed Central. Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months
23
PubMed Central. Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study
24
PubMed. Economic evaluation of oral Nirmatrelvir/ritonavir versus best supportive care in patients at high risk for progression to severe COVID-19 in Germany
25
PubMed Central. Public Health Impact of Paxlovid as Treatment for COVID-19, United States
26
PubMed Central. Emergency Use Authorizations (EUAs) Versus FDA Approval: Implications for COVID-19 and Public Health